Invention Grant
- Patent Title: Sustained-release dosage forms of ruxolitinib
-
Application No.: US18090547Application Date: 2022-12-29
-
Publication No.: US11896717B2Publication Date: 2024-02-13
- Inventor: Yong Ni , Bhavnish Parikh , Krishnaswamy Yeleswaram , Susan Erickson-Viitanen , William V. Williams
- Applicant: INCYTE CORPORATION , INCYTE HOLDINGS CORPORATION
- Applicant Address: US DE Wilmington
- Assignee: Incyte Holdings Corporation,Incyte Corporation
- Current Assignee: Incyte Holdings Corporation,Incyte Corporation
- Current Assignee Address: US DE Wilmington; US DE Wilmington
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- The original application number of the division: US16190883 2018.11.14
- Main IPC: A61K9/20
- IPC: A61K9/20 ; A61K31/519
Abstract:
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Public/Granted literature
- US20230136579A1 SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB Public/Granted day:2023-05-04
Information query
